BIIB
BIOGEN INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$250.91
+0.79%Year over year
Reported trailing growth
- Revenue
- +3.1%
- EBITDA
- -58.5%
- EBIT
- -67.8%
- EPS
- -78.6%
- Free cash flow
- +2.9%
- Operating cash flow
- -8.4%
Forward estimates
Based on analyst estimates
- Revenue
- +3.4%
- EBITDA
- +154.1%
- EPS
- +525.7%
Three-year CAGR
- Revenue
- -1.2%
- EBITDA
- -5.9%
- EBIT
- -13.4%
- Net income
- -24.8%
- EPS
- -25.0%
- Free cash flow
- +21.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026